First published: 21st March 2024

Recognized for its Novel Medical-Grade EEG Headset and Cutting Edge Neuroassessment Platform Focused on Advancing Clinical Neuroscience Research.

Cumulus Neuroscience has been named to Fast Company’s prestigious list of the World’s Most Innovative Companies of 2024. This year’s list shines a spotlight on businesses that are shaping industry and culture through their innovations. These organizations are setting new standards and achieving remarkable milestones in all sectors of the economy. Alongside the World's 50 Most Innovative Companies, Fast Company recognizes 606 organizations across 58 sectors and regions.

Cumulus Neuroscience is recognized in the medical device category for its first-in-class electroencephalogram (EEG) headset and neuroassessment platform. The novel 16 lead dry-sensor EEG headset – which is FDA 510(k) cleared and UKCA marked – is designed to obtain clinical-grade data in remote settings to monitor and evaluate neurological activity. The headset synchronizes with tablet-based functional assessments for use in-clinic or at home, allowing for increased ease-of-use for patients, caregivers, and clinical research teams.

“This recognition from Fast Company reinforces Cumulus’ commitment to driving innovation that advances the science for millions of patients living with neurodegenerative and neuropsychiatric conditions,” said Aman Bhatti, MD, CEO, Cumulus Neuroscience. “Standard lab-based EEG systems require a trained technician, up to 45 minutes to set up, and the application of many wires and gel to a patient’s head, which can be intimidating and uncomfortable. The Cumulus Neuroassessment Platform, which includes our FDA 510(k) cleared EEG headset, removes those barriers entirely. We are excited about the possibilities the platform creates for the future of CNS drug development and more broadly, the future of healthcare.

The World's Most Innovative Companies stands as Fast Company's hallmark franchise and one of its most anticipated editorial efforts of the year. It serves as a definitive chronicle of the novel ideas transforming business and society, providing a snapshot and a road map for the future of innovation across the most dynamic sections of the economy. Companies are selected based on innovation, impact, timeliness, and relevance.

“Our first-in-class AI-driven neuroassessment platform was purpose built with input from ten top pharma companies to frequently and objectively sample a broad spectrum of domain measurements in clinical studies, from behavioural symptoms to functional neurophysiology,” said Brian Murphy, PhD, Founder and Chief Scientific Officer, Cumulus Neuroscience. “We are honored to have our innovative solution that addresses many challenges in biopharma neuroscience clinical research recognized by Fast Company. Our dry-sensor, easy-to-use EEG headset is precisely synchronized to tablet-based assessments alongside a scalable cloud infrastructure that enables data management, analytics and data visualization. Importantly, we have validated that it is feasible for patients living with mild to moderate Alzheimer’s disease to use our platform and adhere to a robust study protocol.”

Cumulus continues to advance its EEG headset and data platform, providing biopharma partners and collaborators with a suite of state-of-the-art tools to help advance the discovery and development of new therapies for neuropsychiatric and neurodegenerative conditions. To learn more, visit www.cumulusneuro.com.

With a mission to generate the data and insights required to accelerate diagnosis and management of central nervous system (CNS) disorders for millions of patients and caregivers around the world, Cumulus Neuroscience is advancing an AI-based, multi-domain digital biomarker platform to enable better, faster decision making in neurology and neuropsychiatry clinical trials and patient care. Designed for and with 10 of the world's leading pharma companies, the platform enables decentralized trials, and is already making a difference in the development of therapies for Alzheimer's Disease, depression and schizophrenia.

Designed to provide an industry-wide standard for real-world measurement of disease progression, Cumulus combines patented technology, in-house expertise and key industry partnerships to capture large amounts of real-world, clinical data repeated over time, across multiple behavioral and physiological domains in the patient's home – all with a US FDA 510(k) cleared and UKCA marked EEG Headset synced to a novel, tablet-based neuroassessment platform. Together with machine learning (ML) analytics and the world's largest database of annotated, longitudinal, neurofunctional data, Cumulus simplifies and improves the robustness of neuroscience clinical trials to provide the best and most cost-effective assessment of CNS treatment outcomes.

The Company is supported by highly experienced specialized investors, DDF/SV Health Investors, LifeArc and Future Fund, and a world-class Scientific and Technical Advisory Board.

Fast Company is the only media brand fully dedicated to the vital intersection of business, innovation, and design, engaging the most influential leaders, companies, and thinkers on the future of business. Headquartered in New York City, Fast Company is published by Mansueto Ventures LLC, along with our sister publication Inc., and can be found online at www.fastcompany.com.